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6Background: Clinical trials are most informative
for evidence-based decision making when they
consistently measure and report outcomes of
relevance to stakeholders. We aimed to assess
the scope and consistency of outcomes
reported in trials for hemodialysis.
Study Design: Systematic review.
Setting & Population: Adults requiring mainte-
nance hemodialysis enrolled in clinical trials.
Selection Criteria: All Cochrane systematic re-
views of interventions published by August 29,
2016, and the trials published and registered in
ClinicalTrials.gov since January 2011.
Interventions: Any hemodialysis-related
interventions.
Outcomes: Frequency and characteristics of the
reported outcome domains and measures.
Results: From the 362 trials, we extracted and
classiﬁed 10,713 outcome measures (a median
of 21 [IQR, 10-39] per trial) into 81 different
outcome domains, of which 42 (52%) were2surrogate; 25 (31%), clinical; and 14 (17%), pa-
tient reported. The number of outcome measures
reported signiﬁcantly changed over time. The 5
most commonly reported domains were all sur-
rogates: phosphate (125 [35%] trials), dialysis
adequacy (120 [33%]), anemia (115 [32%]), in-
ﬂammatory markers (114 [31%]), and calcium
(109 [30%]). Mortality, cardiovascular diseases,
and quality of life were reported very infrequently
(73 [20%], 44 [12%], and 32 [9%], respectively).
Limitations: For feasibility, we included a sam-
pling frame that included only trials identiﬁed in
Cochrane systematic reviews or ClinicalTrials.gov.
Conclusions: Outcomes reported in clinical trials
involving adults receiving hemodialysis are
focused on surrogate outcomes, rather than
clinical and patient-centered outcomes. There is
also extreme multiplicity and heterogeneity at
every level: domain, measure, metric, and time
point. Estimates of the comparative
effectiveness of available interventions are
unreliable and improvements over time have
been inconsistent.Worldwide, an estimated US $240 billion is investedannually into biomedical research, and about half
this funding is from governmental or nonprofit sources.1,2
It is estimated that 85% of the total investment is wasted
due to problems with how research is prioritized,
designed, reported, and disseminated.1,3-7 A major cause
of this postulated waste may be attributed to the way that
outcomes are measured and reported. Many outcomes
reported may have limited clinical or policy relevance,
important domains may not be reported, and different
measures may have been used. Collectively, these prob-
lems may make reliable judgments about the relative ef-
fects of interventions difficult and the clinical and policy
relevance of published research findings substantially
uncertain.8
The unreliability of trials introduced by the selective
reporting of outcomes in favor of statistically significant
outcomes (outcomes reporting bias) and the use of
nonvalidated surrogates are well recognized.9 The more
fundamental problem of prioritizing research questions
based on commercial or other considerations rather
than the needs of patients, clinicians, and regulators andthe focus on outcomes that may not be critically rele-
vant to the end-users of research have also been
highlighted.9-12 Despite these major concerns, detailed
empirical evaluations of the scope and variability
of outcomes in randomized trials and at every
level—domain, measurement, threshold, and time
point—are sparse.
Hemodialysis is one of the most costly interventions
used in health care and imposes an immense burden on
health care systems and people.13-15 An estimated 2
million people with end-stage kidney disease depend on
hemodialysis globally; these patients have a mortality rate
of 27 deaths per 100 patient-years in the 4 first months
after dialysis therapy initiation, which exceeds that of the
general population by more than 10-fold.16-19 Hemodi-
alysis is also an invasive and demanding treatment that
requires patients to be attached to a machine for 10 to 30
hours per week, with devastating consequences on quality
of life.20-23 Although the research investment in hemo-
dialysis has been substantial, the translation into im-
provements in patient outcomes has been modest at
best.24 The aims of this study were to describe the scope,AJKD Vol 72 | Iss 1 | July 2018
Original Investigationquality, and consistency of outcome domains and mea-
sures in hemodialysis trials to inform strategies to
improve outcome selection and reporting and thereby
increase the value of future trials to inform clinical
decisions.. Acute haemodialysis (n=27)
. Non-intervenonal trials (n=16)
. Duplicate publicaon/trials (=25)
. Protocol (n=12)
Record idenﬁed in Cochrane Database of 
Systemac Reviews (CDSR) - Cochrane 
Kidney and Transplant Group Reviews 
. Did not include paents on 
haemodialysis (n=136)
. Did not include paents on 
haemodialysis (n=126)
Trials registered in ClinicalTrials.gov for 
chronic haemodialysis with
published results
N=365 N=263
Reasons for exclusion
Reviews excluded, N=126
Trials included
N=151
Trials excluded, N=266
(n= 31 895 parcipants*)
Total number of trials included in 
Cochrane Systemac Reviews that 
enrolled  paent on haemodialysis 
N=25
Trials included
N=64
(n= 10 186 parcipants)
. Non randomised controlled trials 
(n=35)
N=298
Reasons for exclusion
. Non English language (n=8)
. Paediatric trials (n=7)
Reviews that enrolled paents on 
haemodialysis
Total trials included
N=362
(n= 42 081 parcipants*)
*sample size unknown in three trials
*sample size unknown in three trials
Figure 1. Search results.Methods
Selection Criteria
We searched the Cochrane Database of Systematic Re-
views to identify all systematic reviews that included
trials involving prevalent patients on maintenance he-
modialysis therapy up to August 29, 2016, without
language restriction. Search terms are given in Item S1.
From each systematic review, we obtained the full text of
randomized controlled trials from the list of included
studies. To obtain a contemporary sample, we also
searched ClinicalTrials.gov (from January 2011 to August
29, 2016) for all published trials that enrolled prevalent
patients treated by maintenance hemodialysis and had
analyzed published results from the trials. We excluded
trials that did not include adults (defined as those
aged ≥18 years).
Data Extraction
For each trial, we extracted the following trial character-
istics: first author, year of publication, participating
countries, sample size, mean age of participants, study
duration, intervention type, primary outcome, and all
outcomes/outcome measures. An outcome measure was
defined as any measurement or event reported separately
for all trial arms. All levels of specification of the outcome
measures were extracted if reported: domain (eg, kidney
function), specific measurement (eg, estimation of
glomerular filtration rate by the MDRD [Modification of
Diet in Renal Disease] Study equation), method of aggre-
gation (percentage change), specific metric (between the
start and end of the study period),25,26 and time frame in
relation to the commencement of the trial and the measure
of the outcome.
Analysis
Outcome measures from all included trials were grouped
into outcome domains by 2 reviewers (B.S. and G.W.)
independently and discrepancies were discussed to reach
agreement. The list of outcome domains was reviewed and
agreed on by 4 reviewers (A.T., B.S., G.W., and J.C.C.).
Reviewer B.S. grouped all outcome domains into 3
categories: surrogate (biochemical or physiologic out-
comes that may or may not be validated), clinical (medical
outcomes based on clinician assessment or diagnosis), and
patient reported (outcomes reported by patients usually
relating to quality of life or symptoms), using standard
definitions.27,28 The classification was agreed on by 2 re-
viewers (A.T. and J.C.C.).
The number of trials that reported each outcome
domain was then calculated. The primary outcome, ifAJKD Vol 72 | Iss 1 | July 2018specified, was identified and we noted whether multiple
primary outcomes were reported in the same trial. For
feasibility reasons, we were unable to evaluate the different
outcome measures for all 81 outcome domains, but limited
our detailed measure-specific analysis to 2 selected
frequently reported outcome domains in each category (6
in total), including the measurement, aggregation, metric,
and timing reported. We performed 3 sensitivity analyses:
excluding trials of less than 3 months in duration, trials of
20 or fewer patients, and trials published after 2010. We
compared characteristics of the outcome domains, primary
outcomes, and outcome measures by intervals (1977-1980,
then 5-year intervals for 1981-2015) with binomial
regression, analysis of variance, and χ2 tests. We performed
statistical analyses using R, version 3.2.3 (R Foundation for
Statistical Computing) to evaluate change over time.Results
Trial Characteristics
We identified a total of 362 trials involving 42,081 par-
ticipants (Fig 1). Trial characteristics are provided in
Table 1. The trials were conducted in 49 countries,
including the United States (90 [25%] trials), Italy (31
[9%]), Germany (21 [6%]), Canada (18 [5%]), and Japan63
Table 1. Characteristics of Included Trials
Trial Characteristic No. of Trials (%)
Year of publication
1977-1979 3 (0.8%)
1980-1989 22 (6.1%)
1990-1999 89 (24.6%)
2000-2009 158 (43.6%)
2010-2015 90 (24.9%)
Country
United States 90 (24.9%)
Italy 31 (8.6%)
Germany 21 (5.8%)
Canada 18 (5.0%)
Japan 17 (4.7%)
Greece 16 (4.4%)
United Kingdom 15 (4.1%)
Australia 11 (3.0%)
Netherlands 11 (3.0%)
Other 112 (30.9%)
Multinational studies 20 (5.5%)
Sample size
1-50 211 (58.3%)
51-100 66 (18.2%)
101-150 29 (8.0%)
151-200 18 (5.0%)
>200 35 (9.7%)
Not reported 3 (0.8%)
Duration of trial
≤3 mo 122 (33.7%)
>3-6 mo 89 (24.6%)
>6-9 mo 26 (7.2%)
>9-12 mo 63 (17.4%)
>12 mo 57 (15.7%)
Not reported 5 (1.4%)
Intervention type
Pharmacologic 161 (44.5%)
Dialysis techniques 115 (31.8%)
Exercise 40 (11.0%)
Vascular access care 43 (11.9%)
Psychological 3 (0.3%)
No. of unique outcome measures reported in each trial
0-10 213 (58.8%)
11-25 118 (32.6%)
26-50 26 (7.1%)
>50 5 (1.4%)
Note: N = 362 trials.
Original Investigation(17 [5%]). Twenty (6%) trials involved sites in more than
one country. The year of trial publication ranged from
1977 to 2015, median duration of trials was 6 (inter-
quartile range [IQR]), 3-12) months, and median sample
size was 42 (IQR, 23-85) patients.
Outcome Measures and Domains
In total, 10,713 outcome measures were reported across
362 trials. The number of outcome measures (inclusive of
time points) ranged from 1 to 196, with a median of6421 (IQR, 10-39) per trial (the same outcome measure
with 2 time points was counted as 2 different measures;
eg, mean serum calcium at 6 months and mean serum
calcium at 12 months). The number of unique outcome
measures (exclusive of time points) ranged from 1 to 63
(median, 9 [IQR, 5-16]) per trial. Sixty-seven outcome
measures were excluded because they were not consid-
ered relevant to prevalent patients receiving hemodialysis
(eg, “number starting dialysis”) or were specific to
a single intervention within the trial (eg, “abrasion
from ergometer” and “change from anergic to reactive”).
The remaining 10,646 were classified into 81 outcome
domains, which were grouped into 3 categories: surrogate
(42 [52%]), clinical (25 [31%]), and patient-reported
outcomes (14 [17%]).
The proportion of trials reporting each outcome
domain is provided in Figure 2. The 5 most commonly
reported domains were all surrogates: phosphate con-
centration (125 [35%] trials), dialysis adequacy (120
[33%]), anemia (115 [32%]), inflammatory markers/
oxidative stress (114 [31%]), and calcium concentra-
tion (109 [30%]). Mortality and cardiovascular disease
were reported in 73 (20%) and 44 (12%) trials,
respectively. Quality of life and fatigue/energy were
reported in 32 (9%) and 35 (10%) trials, respectively.
The number of trials reporting at least 1 surrogate
outcome domain was 322 (89%); 211 (58%) trials re-
ported at least 1 clinical outcome domain, and 128 (35%)
trials reported at least 1 patient-reported outcome. Of the
26 (32%) outcomes reported by at least 10% of trials,
18 (22%) were surrogate; 6 (7%), clinical; and 2 (3%),
patient reported.
Forty-nine (60%) outcome domains had more than
10 different outcome measures (exclusive of time
point). The range of specific outcome measures for 6
outcome domains (2 selected outcome domains for
surrogate, clinical, and patient-reported outcomes) and
the time points of measurement are provided in Fig 3A
to F. For the category surrogate outcome, we assessed
“serum phosphate” and “serum calcium,” which had 35
(254 including time points) and 35 (258 including time
points) different measures used across all trials, respec-
tively (Fig 3A and B). For clinical outcomes, “mortality”
and “cardiovascular diseases” had 48 (123 including
time points) and 47 (109 including time points)
different outcome measures, respectively (Fig 3C
and D). The patient-reported outcomes of “pain” and
“fatigue/energy” had 40 (81 including time points) and
18 (47 including time points) measures, respectively
(Fig 3E and F).
Characteristics of Primary Outcomes
Across the 362 trials, 230 (64%) did not specify the pri-
mary outcome, 40 (11%) specified several primary out-
comes, and 92 (26%) specified one unique primary
outcome. The outcomes specified as primary outcomes
corresponded to 35 different outcome domains: 19 (54%)AJKD Vol 72 | Iss 1 | July 2018
Figure 2. Number of trials reporting each outcome domain (total 362 trials, 81 outcome domains). Proportions are expressed in
a ×10 log scale to display proportion <1%. Abbreviation: BMI, body mass index.
Original Investigationwere surrogate outcomes, 10 (29%) were clinical out-
comes, and 6 (17%) were patient-reported outcomes. The
6 most frequently reported primary outcomes were
vascular access (35 [27%] trials), mortality (20 [15%]
trials), parathyroid hormone (15 [11%] trials), cardiac
function (12 [9%] trials), anemia/hemoglobin/iron
(8 [6%] trials), and inflammatory markers/oxidative stress
(8 [6%] trials). The proportion of trials reporting each
primary outcome domain is provided in Table S1.
Comparison of Outcome Characteristics Over Time
The number of outcomes reported significantly changed
over time (P < 0.001) and appeared to increase, especially
during the past 10 years (Fig S1). The proportion of trialsAJKD Vol 72 | Iss 1 | July 2018that reported at least 1 clinical outcome significantly
changed over time (P < 0.001), but the proportion of
trials that reported at least 1 surrogate and 1 patient-
reported outcome was stable (P = 0.1 and P = 0.7,
respectively; Fig 4). The proportion of trials that specified
a primary outcome significantly changed over time
(P < 0.001). The type of outcome (clinical, patient-
reported, or surrogate) did not change over time
(P = 0.07); however, there was an increase in the
reporting of clinical outcomes from 1991 to 2005
(Fig 5). The number of unique measures for each of the
6 selected clinical, surrogate, and patient-reported out-
comes continued to expand significantly during the study
period (Table 2).65
A B
Figure 3. Frequency of outcome measures (deﬁnitions and time points) among trials reporting: (A) phosphate concentrations (124
trials, 35 outcome measures), (B) calcium concentrations (109 trials, 35 outcome measures), (C) mortality (74 trials, 48 outcome
measures), (D) cardiovascular diseases (44 trials, 47 outcome measures), (E) pain (57 trials, 40 outcome measures), and (F)
fatigue/energy (34 trials, 18 outcome measures). Abbreviations: LV, left ventricular; pts, patients; PTH, parathyroid hormone;
SF-36, 36-Item Short Form Health Survey; VAS, visual analogue scale.
Original InvestigationSensitivity Analysis
We performed a sensitivity analysis and excluded trials of
less than 3 months in duration (69 trials). Across the 293
remaining trials, 9,139 outcome measures were reported,
which were classified into 81 outcome domains and
grouped into 3 categories: surrogate (42 [51%]), clinical
(25 [31%]), and patient-reported (14 [17%]) outcomes.
We performed a second sensitivity analysis and excluded
trials of 20 or fewer patients (79 trials). Across the 283
remaining trials, 8,241 outcome measures were reported,66which were classified into 80 outcome domains and
grouped into 3 categories: surrogate (42[53%]), clinical
(24 [30%]), and patient-reported (14 [17%]) outcomes.
We performed a third sensitivity analysis and excluded trials
published after 2010 (81 trials). Across the 281 remaining
trials, 8,089 outcome measures were reported, which
were classified into 81 outcome domains and grouped into
3 categories: surrogate (42 [51%]), clinical (25 [31%]),
and patient-reported (14 [17%]) outcomes. Compared
with all trials, the proportion of trials that reported eachAJKD Vol 72 | Iss 1 | July 2018
CFigure 3. (cont’d).
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DFigure 3. (cont’d).
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Original Investigationoutcome domain was similar for trials of 3 or more months’
duration, trials of more than 20 patients, and trials pub-
lished before 2011 (Table S2).Discussion
The outcome domains reported in clinical trials involving
adults receiving hemodialysis are heavily focused on sur-
rogate outcomes, rather than clinical and patient-centered
outcomes such as mortality, cardiovascular disease, and
quality of life, so that the importance of the clinical trial
results to clinical practice and policy are substantially un-
certain. Moreover, the outcomes are extremely numerous
and heterogeneous across trials at every level—domain,
measurement, method of aggregation, metric, and time
point, making it very difficult to evaluate the comparative
effectiveness of interventions.
Three major issues regarding the reporting of outcomes
in this setting have been identified. First, the outcomes re-
ported lack clinical and policy relevance. Second, outcomes
of clear relevance are seldom reported, and third, extreme
heterogeneity and multiplicity of outcomes are evident, so
that the comparability of interventions is difficult to ascer-
tain and outcomes reporting bias are made more likely.
More than 80% of outcome measures were biomarkers,
with serum phosphate, dialysis adequacy, anemia/hemo-
globin/iron, inflammatory markers/oxidative stress, and
calcium as the top 5 most frequently reported outcome
domains. However, hemodialysis is notable because it
lacks a validated biomarker. Changes in serum phosphate,
serum calcium, parathyroid hormone, and hemoglobin
concentrations have not been shown to predict changes in
mortality and cardiovascular events in randomized trials in
patients receiving hemodialysis.29,30 The clinical relevance
of trials that report these outcomes therefore remains un-
certain at best, even if results of interventions were
favorable.28,31-34 This may be even more important if
patient-important outcomes such as functional, social, and
emotional well-being, either directly or indirectly affected
by the intervention, are not reported.4,11,35 We suggest
that further research is needed to strengthen the causal link
between surrogates and clinical outcomes so that they can
be used to improve trial efficiency.
Conversely, most trials did not report outcomes that
most would regard as important and highly relevant
outcomes to patients receiving hemodialysis and their
clinicians. Quality of life was reported in just 32 (9%)
trials, with mortality and cardiovascular end
points being reported in only 73 (20%) and 44 (12%)
trials, respectively.31 Studies across medical specialties,
including nephrology, have consistently shown that
patient-important outcomes in trials are uncommon. For
example, only 93 of 413 (23%) trials in cardiovascular
disease and 78 of 436 (18%) trials in diabetes included
patient-centered outcomes.10,11 In nephrology, of the 66AJKD Vol 72 | Iss 1 | July 2018
EFigure 3. (cont’d).
AJKD Vol 72 | Iss 1 | July 2018 69
Original Investigation
Figure 4. Difference in the proportion of trials that reported at lea
F
Figure 3. (cont’d).
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Original Investigationsystematic reviews focused on the prevention of pro-
gression to end-stage kidney disease, 5 (8%) reviews
assessed quality of life.12 The priorities of patients with
end-stage kidney disease include quality of life, anxiety,
and fatigue, but these outcomes were rarely evaluated in
hemodialysis trials.36,37 The omission of patient-centered
outcomes undermines the ability of the study to inform
shared decision making in the context of effective treat-
ments and care that takes into consideration the patient’s
priorities and values. Despite the increasing interest in
using patient-reported outcomes measures in clinical tri-
als, it remains a challenge.38 Compared with surrogate
end points, clinical outcomes and patient-reported out-
comes may be more challenging to include in trials
because they would generally require more time and
resources and a larger sample size. Specific challenges
for patient-reported outcomes include the lack of
well-validated measures for use in the chronic kidney
disease population and uncertainty about what outcomes
and outcome measures to use.39,40 Establishing core
outcome domains that are important to patients and
health professionals and identifying or developing
validated and feasible measures for use in trials may help
address these challenges.41
There is a need to identify outcomes that are important
to patients, then establish standardized, well-defined,
responsive, and psychometrically robust patient-reported
outcome measures for outcome domains that are relevant
to patients.38 It has been recommended that specific
patient-reported outcome measures should at least focus
on “core, disease-related symptoms or on the functional
effects of a disease, which may be affected by the inter-
vention.”42(p 143) These findings may reflect that impor-
tant outcomes are not being measured or an outcomest 1 clinical, patient-reported, and surrogate outcome over time.
AJKD Vol 72 | Iss 1 | July 2018
Figure 5. Differences in the categories of primary outcomes over time and the proportion of trials that speciﬁed a primary outcome
over time.
Original Investigationreporting bias whereby only outcomes in favor of the
intervention are being reported.43,44
Our findings highlight the extreme multiplicity and
heterogeneity in the outcome domains and measures
across trials in hemodialysis with 81 different outcome
domains and 10,713 outcome measures reported. For
example, serum phosphate (the most frequently reported
outcome) was measured in 125 (35% of trials), yet had 35
different outcome measures. Differences in nomenclature,
thresholds, and terms used for the same outcome can
preclude comprehensive and systematic assessments of the
comparative effect of interventions. Some of the differ-
ences in outcomes may be due to changes in interventions
and understanding of methodology that have evolved over
time. We speculate that such heterogeneity is not limited
to hemodialysis but would be found in other medical
specialties. However, we are not aware of other studies
that have systematically assessed the reporting of all
outcome domains and at the level of outcome measures
inclusive of definition, threshold, and time points.45-47Table 2. Number of New Measures Reported in Trials Published O
Reported Domains
Outcome
Domain
Total No. of
Measures
No. of New Measures by
1977-
1980
1981-
1985
1986-
1990
Mortality 48 0 0 0
Cardiovascular
disease
47 0 1 1
Pain 40 1 0 3
Fatigue/energy 18 0 0 0
Phosphate 35 1 2 3
Calcium 35 4 3 5
Note: Difference in the number of new outcome measures per domain over time.
AJKD Vol 72 | Iss 1 | July 2018Our study addresses an evidence gap by providing a
detailed analysis of the scope and consistency of outcome
domains, down to the level of outcome measures, across a
large selection of hemodialysis trials. However, we
acknowledge some potential limitations. Because it was not
feasible to include all trials in hemodialysis, Cochrane
systematic reviews and ClinicalTrials.gov were used as a
sampling frame, potentially introducing selection bias.
Because we did not include all trials and because trials in
Cochrane reviews would be similar in addressing the same
topic, we expect that our results may underestimate the
scope, inconsistency, and variability of outcome reporting.
The older studies included were from Cochrane systematic
reviews and any trends may be confounded with these
sources, and given the smaller number of older trials, the
estimates may be less reliable. Cochrane systematic reviews
of randomized controlled trials probably cover most of the
major topics and probably include most of the prominent
and “landmark” randomized controlled trials in
nephrology.48ver Time Periods for 6 Selected Clinical, Surrogate, and Patient-
Time Period P for
Change
Over Time
1991-
1995
1996-
2000
2001-
2005
2006-
2010
2011-
2015
1 5 14 18 37 <0.001
5 10 24 11 30 <0.001
9 7 19 5 16 <0.001
3 4 9 7 7 0.01
9 12 16 5 13 0.01
11 11 22 6 15 <0.001
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Original InvestigationThis work provides empirical evidence for the need to
standardize outcome reporting in trials. Major initiatives
have been forged to establish a consensus-based standard-
ized set of core outcomes. A core outcome set is an agreed
minimum set of outcomes to be measured and reported in
all clinical trials of a specific disease or trial population, to
ensure that the results of studies can be compared, con-
trasted and combined as appropriate, and to ensure all trials
contribute relevant and usable information.41,49,50 How-
ever, researchers can add other relevant outcomes, for
example, outcomes that may be disease or condition spe-
cific. The Outcome Measures in Rheumatology (OMER-
ACT), established in 1992, is the pioneering initiative for
developing core outcomes, which has improved the con-
sistency and reporting of outcomes in rheumatology tri-
als.26,51,52,53 The World Health Organization and the US
Food and Drug Administration support the validity of
OMERACT methodology for developing core outcomes.54
Now, there are more than 720 references of core outcome
projects that span hundreds of disease areas registered in the
Core Outcome Measures in Effectiveness Trials (COMET)
database. A core outcome set is to be used as a minimum in
trials for a given health condition because they are critically
important to patients and health professionals.41 To com-
plete a core outcome domain, establishing standardized
outcomemeasures to enable themeasurement and reporting
of core outcome domains to inform shared decision-making
among patients and their clinicians is needed.55 Further
research may also be conducted to ascertain the perspectives
of funding agencies and industry on implementing core
outcomes in trials, to inform strategies for ensuring that
important outcomes are reported in trials.
A broad array of outcomes is reported in trials of in-
terventions in hemodialysis, and most are biochemical end
points. There is considerable multiplicity and heterogeneity
in the outcomes chosen by clinical trialists to be measured
and reported, from domain through to measurement,
method of aggregation, metric, and timing across trials. The
development of a core outcome set for hemodialysis trials
that is based on the priorities of patients, caregivers, and
health professionals is needed and now is underway by the
Standardized Outcomes in Nephrology (SONG) initiative.56
The core outcome set proposed by the SONG-HD (SONG-
Hemodialysis) initiative57 is aimed to be relevant and
feasible for pragmatic trials. Investigatorswould be expected
to add other outcomes based on the type of trial (eg, pilot vs
a larger definitive trial), population, and scientific rationale
of the intervention. This initiative is hoped to lead to better
outcome reporting and increase the value of trials for
treatment decision making, ultimately leading to improve-
ments for patients in outcomes important and relevant
to them.Supplementary Material
Figure S1: Number of outcome measures reported in clinical trials
over 5-year intervals.72Item S1: Search terms.
Table S1: Primary outcomes reported in 132 trials.
Table S2: Sensitivity analysis of proportion of trials that reported
each outcome domain.
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